Evidence map›Paper›PMID 18055791›Full record

ArticleInvestigative ophthalmology & visual science2007

A novel form of transducin-dependent retinal degeneration: accelerated retinal degeneration in the absence of rod transducin.

Elliott Brill, Katherine M Malanson, Roxana A Radu, Natalia V Boukharov, Zhongyan Wang, Hae-Yun Chung, Marcia B Lloyd, Dean Bok, Gabriel H Travis, Martin Obin and 1 more

Open access · greenAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Aggregation of the Constitutively Active K296E Rhodopsin Mutant Contributes to Retinal Degeneration.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Article
  4. Article
  5. MRI of Retinal Free Radical Production With Laminar Resolution In Vivo.Investigative ophthalmology & visual science · 2016
    Article
  6. A Novel, Real-Time, In Vivo Mouse Retinal Imaging System.Investigative ophthalmology & visual science · 2015
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Elliott BrillMolecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts, USA.
Katherine M Malanson
Roxana A Radu
Natalia V Boukharov
Zhongyan Wang
Hae-Yun Chung
Marcia B Lloyd
Dean Bok
Gabriel H Travis
Martin Obin
Janis Lem
Tufts Medical Center · USDoheny Eye Institute · USArthur M. Sackler Gallery · US

Funding

Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gregory Darin Field, DAVID S WILLIAMS · 1985 to 2026
$16.8M
The Role of Muller Cells in Visual Pigment RegenerationR01EY011713 · NEI · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI TRAVIS, GABRIEL H · 1997 to 2017
$6.9M
RHODOPSIN MUTANTSR01EY012008 · NEI · TUFTS MEDICAL CENTER · PI LEM GEE, JANIS · 1998 to 2010
$4.1M
THE PATHOBIOLOGY OF INHERITED RETINAL DEGENERATIONR01EY000444 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOK, DEAN · 1985 to 2006
$3.6M
Signaling in the retina and retinal pigment epitheliumZ01EY000444 · NEI · NATIONAL EYE INSTITUTE · PI REDMOND, THOMAS · 2007 to 2008
$3.4M
Supplement to Core Grant for Vision ResearchP30EY013078 · NEI · TUFTS MEDICAL CENTER · PI PANJWANI, NOORJAHAN · 2001 to 2005
$3.0M
Biochemical and Genetic Analysis of the Visual CycleR01EY015844 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TRAVIS, GABRIEL H · 2005 to 2009
$1.9M
Synapse Neurobiology Training ProgramT32NS061764 · NINDS · TUFTS UNIVERSITY BOSTON · PI BIEDERER, THOMAS · 2009 to 2019
$1.7M
Video Display for the Visually ImpairedR44EY012912 · NEI · MICROOPTICAL ENGINEERING CORPORATION · PI RENSING, NOA M · 2001 to 2003
$793k
VIDEO DISPLAY FOR THE VISUALLY IMPAIREDR43EY012912 · NEI · MICROOPTICAL ENGINEERING CORPORATION · PI SPITZER, MARK B · 2000 to 2000
$99k
Intramural NIH HHS Z01 EY000444NEI NIH HHS EY00331NEI NIH HHS EY015844NEI NIH HHS EY11713NEI NIH HHS EY12008NEI NIH HHS F2EY12912ANEI NIH HHS P30 EY000331NEI NIH HHS P30 EY013078NEI NIH HHS P30 EY13078NEI NIH HHS R01 EY000444NEI NIH HHS R01 EY011713NEI NIH HHS R01 EY012008NEI NIH HHS R01 EY015844NEI NIH HHS R43 EY012912NEI NIH HHS R44 EY012912NINDS NIH HHS T32 NS061764
6 · The paper itself

Abstract

purposeRhodopsin mutations account for approximately 25% of human autosomal dominant retinal degenerations. However, the molecular mechanisms by which rhodopsin mutations cause photoreceptor cell death are unclear. Mutations in genes involved in the termination of rhodopsin signaling activity have been shown to cause degeneration by persistent activation of the phototransduction cascade. This study examined whether three disease-associated rhodopsin substitutions Pro347Ser, Lys296Glu, and the triple mutant Val20Gly, Pro23His, Pro27Leu (VPP) caused degeneration by persistent transducin-mediated signaling activity.

methodsTransgenic mice expressing each of the rhodopsin mutants were crossed onto a transducin alpha-subunit null (Tr(alpha)(-/-)) background, and the rates of photoreceptor degeneration were compared with those of transgenic mice on a wild-type background.

resultsMice expressing VPP-substituted rhodopsin had the same severity of degeneration in the presence or absence of Tr(alpha). Unexpectedly, mice expressing Pro347Ser- or Lys296Glu-substituted rhodopsins exhibited faster degeneration on a Tr(alpha)(-/-) background. To test whether the absence of alpha-transducin contributed to degeneration by favoring the formation of stable rhodopsin/arrestin complexes, mutant Pro347Ser(+), Tr(alpha)(-/-) mice lacking arrestin (Arr(-/-)) were analyzed. Rhodopsin/arrestin complexes were found not to contribute to degeneration.

conclusionsThe authors hypothesized that the decay of metarhodopsin to apo-opsin and free all-trans-retinaldehyde is faster with Pro347Ser-substituted rhodopsin than it is with wild-type rhodopsin. Consistent with this, the lipofuscin fluorophores A2PE, A2E, and A2PE-H(2), which form from retinaldehyde, were elevated in Pro347Ser transgenic mice.

Indexed as

Point MutationAnimalsArrestinGenotypeLipofuscinMiceMice, TransgenicOligopeptidesRetinal DegenerationRetinal Rod Photoreceptor CellsRhodopsinTransducinVision, OcularArrestinLipofuscinOligopeptidesRhodopsinTransducinvalyl-prolyl-proline

Identifiers

PMID18055791
PMCPMC2248236
OpenAlexW2094799545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.